Postmortem Findings of Malignant Pleural Mesothelioma

Finn, R S; Brims, Fraser; Gandhi, Arjun; Olsen, Nola; Musk, Arthur W.; Maskell, Nick A; Lee, Gary

doi:10.1378/chest.11-3204

Cited by 102 publications

(76 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metastases are often determined in postmortem studies. In 7 autopsy studies of 655 patients, the prevalence of CNS metastasis was 2.7% (6)(7)(8)(9)10,11,12). CNS metastases are seen in all histological types of MPM.…”

Section: Discussionmentioning

confidence: 99%

Malignant Pleural Mesothelioma and Central Nervous System Metastases: Report of Two Cases

Özyürek¹,

Erdoğan²,

Ünver³

et al. 2018

Respir Case Rep

View full text Add to dashboard Cite

At the time of diagnosis of malignant pleural mesothelioma (MPM), distant metastases are rare, but can occur through the hematogenous route or an adjacent route. Central nervous system (CNS) metastasis is rarely seen and the incidence is not known. Metastases occur more often in patients with relatively prolonged survival following aggressive treatment. Metastasis most often occurs in the cerebral cortex, cerebellum, intracranial meninges, or the spinal cord. CNS metastases can be seen in all histological types of MPM. Presently described are the cases of 2 patients diagnosed with malignant mesothelioma and in whom a rarely seen cranial metastasis was determined.

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant Pleural Mesothelioma and Central Nervous System Metastases: Report of Two Cases

Özyürek¹,

Erdoğan²,

Ünver³

et al. 2018

Respir Case Rep

View full text Add to dashboard Cite

show abstract

“…In our case, the patient had a solitary subpleural nodule and did not have any pleural thickening or calcification on PET-CT scan. He presented with cranial metastasis, which is identified in about 3% of cases in recent postmortem studies 10. He also had no history of asbestos exposure.…”

Section: Discussionmentioning

confidence: 99%

Rare presentation of a localised malignant pleural mesothelioma with cranial metastasis

2016

View full text Add to dashboard Cite

Mesothelioma is an uncommon malignant neoplasm and a localised form of the pleura is especially very rare. Diagnosis of localised malignant pleural mesothelioma (LMPM) is very challenging. Histopathological verification is the gold standard, and studies such as CT, positron emission tomography (PET) and thoracoscopy are very valuable tools in assisting diagnosis. We report a case of histopathologically proven LMPM, which was discovered as a well circumscribed solitary subpleural nodule on PET-CT after presentation with cranial metastasis. This case shows that LMPM can present with uncommon radiological and clinical appearances, and imaging tools such as PET-CT have a very important role in diagnosis.

show abstract

“…Phenotypically, MPM can develop pleural based nodules, pleural effusions or diffuse pleural thickening [Finn et al 2012]. Imaging of suspected MPM cases reflects these abnormalities.…”

Section: Diagnosis and Imaging Of Mesotheliomamentioning

confidence: 99%

Malignant pleural mesothelioma: an update on diagnosis and treatment options

Kondola

Manners

Nowak

2016

Ther Adv Respir Dis

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) represents a significant diagnostic and therapeutic challenge and is almost always a fatal disease. Imaging abnormalities are common, but have a limited role in distinguishing mesothelioma from metastatic pleural disease. Similarly, minimally invasive biomarkers have shown promise but also have limitations in the diagnosis of mesothelioma. In experienced centers, cytology and immunohistochemistry are now sufficient to diagnose the epithelioid subtype of mesothelioma, which can reduce the need for more invasive diagnostic investigations. Prognosis of MPM is modestly impacted by oncological treatments. Chemotherapy with cisplatin and pemetrexed is considered the standard of care, though the addition of bevacizumab to the platinum doublet may be the new standard of care. New targeted therapies have demonstrated some promise and are being addressed in clinical trials. This review focuses on the current data on the diagnostic and therapeutic issues of MPM.

show abstract

Postmortem Findings of Malignant Pleural Mesothelioma

Cited by 102 publications

References 27 publications

Malignant Pleural Mesothelioma and Central Nervous System Metastases: Report of Two Cases

Malignant Pleural Mesothelioma and Central Nervous System Metastases: Report of Two Cases

Rare presentation of a localised malignant pleural mesothelioma with cranial metastasis

Malignant pleural mesothelioma: an update on diagnosis and treatment options

Contact Info

Product

Resources

About